Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
Bone Marrow Transplant
; 14(4): 635-6, 1994 Oct.
Article
in En
| MEDLINE
| ID: mdl-7858540
ABSTRACT
There have been encouraging reports of the use of recombinant tissue plasminogen activator (tPA) in established veno-occlusive disease (VOD). Haemodialysis has been considered a contraindication to this therapy in view of the potential haemostatic complications. We report a case of a woman who developed moderately severe VOD complicated by anuria following an allogeneic bone marrow transplant for relapsed acute myeloid leukaemia. Following initiation of peritoneal dialysis she received tPA at a dose of 10 mg/day for 5 days. There was rapid improvement in her urine output and liver function with no bleeding complications. This case suggests that the requirement of dialysis may not preclude the use of tPA in established VOD and therefore warrants further study.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hepatic Veno-Occlusive Disease
/
Leukemia, Myeloid, Acute
/
Bone Marrow Transplantation
/
Tissue Plasminogen Activator
Type of study:
Etiology_studies
Limits:
Adult
/
Female
/
Humans
Language:
En
Journal:
Bone Marrow Transplant
Journal subject:
TRANSPLANTE
Year:
1994
Document type:
Article
Affiliation country:
New Zealand